Trial Profile

A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group, Pivotal Trial to Assess the Efficacy and Safety of Sonlicromanol in Adult Subjects With a Genetically Confirmed Mitochondrial DNA tRNALeu(UUR) m.3243A>G Variant

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 13 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 May 2025 According to a Khondrion media release, company announced it has been awarded an Innovation Credit of up to 5 million euro from the Netherlands Enterprise Agency, a government agency that supports entrepreneurs. announced it has been awarded an Innovation Credit of up to 5 million Euro from the Netherlands Enterprise Agency, a government agency that supports entrepreneurs. The Phase 3 trial is expected to launch in H2-2025.
05 Mar 2025 Planned End Date changed from 2 Jul 2027 to 2 Jan 2028.
05 Mar 2025 Planned primary completion date changed from 2 Jul 2027 to 2 Jan 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com